Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA; Marriott Heart Disease Research Program, Division of Cardiovascular Diseases, Departments of Medicine, Molecular Pharmacology and Experimental Therapeutics, and Medical Genetics, Mayo Clinic, Rochester, MN, USA.
J Mol Recognit. 2013 Dec;26(12):679-88. doi: 10.1002/jmr.2313.
Acetyl-CoA carboxylase 2 (ACC2) is an isoform of ACC functioning as a negative regulator of fatty acid β-oxidation. Spot14, a thyroid hormone responsive protein, and Mig12, a Spot14 paralog, have recently been identified as regulators of fatty acid synthesis targeting ACC1, a distinctive subtype of ACC. Here, we examined whether Spot14/Mig12 modulates ACC2. Nanoscale protein topography mapped putative protein-protein interactions between purified human Spot14/Mig12 and ACC2, validated by functional assays. Human ACC2 displayed consistent enzymatic activity, and homogeneous particle distribution was probed by atomic force microscopy. Citrate-induced polymerization and enzymatic activity of ACC2 were restrained by the addition of the recombinant Spot14/Mig12 heterocomplex but only partially by the oligo-heterocomplex, demonstrating that the heterocomplex is a designated metabolic inhibitor of human ACC2. Moreover, Spot14/Mig12 demonstrated a sequestering role preventing an initial ACC2 nucleation step during filamentous polymer formation. Thus, the Spot14/Mig12 heterocomplex controls human ACC2 polymerization and catalytic function, emerging as a previously unrecognized molecular regulator in catalytic lipid metabolism.
乙酰辅酶 A 羧化酶 2(ACC2)是 ACC 的同工酶,作为脂肪酸β氧化的负调节剂。Spot14,一种甲状腺激素反应蛋白,和 Mig12,Spot14 的旁系同源物,最近被鉴定为靶向 ACC1 的脂肪酸合成调节剂,ACC1 是 ACC 的一个独特亚型。在这里,我们研究了 Spot14/Mig12 是否调节 ACC2。纳米级蛋白质形貌图绘制了纯化的人 Spot14/Mig12 和 ACC2 之间假定的蛋白质-蛋白质相互作用,通过功能测定进行了验证。人 ACC2 显示出一致的酶活性,并通过原子力显微镜探测到均匀的颗粒分布。柠檬酸诱导的 ACC2 聚合和酶活性受到重组 Spot14/Mig12 异源复合物的抑制,但仅部分受到寡聚异源复合物的抑制,表明该异源复合物是人类 ACC2 的指定代谢抑制剂。此外,Spot14/Mig12 表现出隔离作用,防止丝状聚合物形成过程中 ACC2 的初始成核步骤。因此,Spot14/Mig12 异源复合物控制着人类 ACC2 的聚合和催化功能,成为催化脂质代谢中以前未被识别的分子调节剂。